Switch theme
Sign up to access all valuation multiples
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
2007
40
LTM Revenue $38.9M
Last FY EBITDA -$63.3M
-$151M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Whitehawk Therapeutics has a last 12-month revenue (LTM) of $38.9M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Whitehawk Therapeutics achieved revenue of $26.0M and an EBITDA of -$63.3M.
Whitehawk Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Whitehawk Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $38.9M | XXX | $26.0M | XXX | XXX | XXX |
| Gross Profit | $14.9M | XXX | $23.0M | XXX | XXX | XXX |
| Gross Margin | 38% | XXX | 88% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$63.3M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -244% | XXX | XXX | XXX |
| EBIT | -$52.0M | XXX | -$64.8M | XXX | XXX | XXX |
| EBIT Margin | -134% | XXX | -249% | XXX | XXX | XXX |
| Net Profit | -$36.9M | XXX | -$63.7M | XXX | XXX | XXX |
| Net Margin | -95% | XXX | -245% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Whitehawk Therapeutics's stock price is $2.
Whitehawk Therapeutics has current market cap of $79.6M, and EV of -$151M.
See Whitehawk Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$151M | $79.6M | XXX | XXX | XXX | XXX | $-1.31 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Whitehawk Therapeutics has market cap of $79.6M and EV of -$151M.
Whitehawk Therapeutics's trades at -5.8x EV/Revenue multiple, and 2.4x EV/EBITDA.
Equity research analysts estimate Whitehawk Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Whitehawk Therapeutics has a P/E ratio of -2.2x.
See valuation multiples for Whitehawk Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $79.6M | XXX | $79.6M | XXX | XXX | XXX |
| EV (current) | -$151M | XXX | -$151M | XXX | XXX | XXX |
| EV/Revenue | -3.9x | XXX | -5.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBIT | 2.9x | XXX | 2.3x | XXX | XXX | XXX |
| EV/Gross Profit | -10.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.2x | XXX | -1.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 2.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialWhitehawk Therapeutics's last 12 month revenue growth is -14%
Whitehawk Therapeutics's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $2.2M for the same period.
Whitehawk Therapeutics's rule of 40 is -282% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Whitehawk Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Whitehawk Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -14% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -244% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -282% | XXX | -258% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 196% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 338% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Whitehawk Therapeutics acquired XXX companies to date.
Last acquisition by Whitehawk Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Whitehawk Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Whitehawk Therapeutics founded? | Whitehawk Therapeutics was founded in 2007. |
| Where is Whitehawk Therapeutics headquartered? | Whitehawk Therapeutics is headquartered in United States of America. |
| How many employees does Whitehawk Therapeutics have? | As of today, Whitehawk Therapeutics has 40 employees. |
| Who is the CEO of Whitehawk Therapeutics? | Whitehawk Therapeutics's CEO is Dr. David James Lennon, PhD. |
| Is Whitehawk Therapeutics publicy listed? | Yes, Whitehawk Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Whitehawk Therapeutics? | Whitehawk Therapeutics trades under WHWK ticker. |
| When did Whitehawk Therapeutics go public? | Whitehawk Therapeutics went public in 2021. |
| Who are competitors of Whitehawk Therapeutics? | Similar companies to Whitehawk Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Whitehawk Therapeutics? | Whitehawk Therapeutics's current market cap is $79.6M |
| What is the current revenue of Whitehawk Therapeutics? | Whitehawk Therapeutics's last 12 months revenue is $38.9M. |
| What is the current revenue growth of Whitehawk Therapeutics? | Whitehawk Therapeutics revenue growth (NTM/LTM) is -14%. |
| What is the current EV/Revenue multiple of Whitehawk Therapeutics? | Current revenue multiple of Whitehawk Therapeutics is -3.9x. |
| Is Whitehawk Therapeutics profitable? | Yes, Whitehawk Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
